TCRX
Tscan Therapeutics Inc
0.2754$
+0.0%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 206.3% | -329.6% | -5,170.8% | -4,892.7% | -2,661.4% | -4,122.1% | -1,731.3% | -1,081.5% | -1,292.9% | -1,246.7% | -2,472.4% | -2,619.9% | -1,635.2% | |
| 33.1% | 17.8% | 221.6% | 208.2% | 97.9% | 106.9% | 31.2% | 22.7% | 30.5% | 28.2% | 70.6% | 66.5% | 40.5% | |
| 34.5% | 20.8% | 350.5% | 434.3% | 240.5% | 408.1% | 157.3% | 106.4% | 119.9% | 78.2% | 251.0% | 224.3% | 138.4% | |
| 730.6% | -86.0% | -372.6% | 407.3% | -26.6% | 790.8% | -294.1% | 12.5% | -14.3% | -460.5% | 112.9% | -43.4% | -162.1% | |
| 36.5% | 6.5% | 124.6% | 160.8% | 130.6% | 133.5% | 70.6% | 41.6% | 56.8% | 6.7% | 7.1% | 46.9% | 30.4% | |
| -1,580.0% | 26.5% | 6,389.2% | -6,290.3% | -7,850.6% | 4,104.2% | 623.2% | 1,574.7% | 1,297.3% | 577.7% | -7.1% | -44.2% | 659.1% | |
| – | – | 0.0% | 0.0% | 0.0% | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -4.5% | 2.4% | – | – | – | 50.1% | – | 6.2% | – | 2.8% | – | 9.4% | – | |
| -6.5% | 0.3% | 45.6% | 30,146.8% | 117.3% | 6,870.7% | -24.2% | 3.8% | 0.0% | 2.8% | 0.0% | 9.4% | 2.4% | |
| -1,380.2% | -302.8% | 1,264.0% | 18,963.8% | -10,394.8% | 6,852.8% | -1,132.2% | 496.9% | 4.5% | -666.1% | -2,479.5% | -2,654.7% | -973.7% | |
| 169.7% | -336.1% | -5,295.4% | -5,053.5% | -2,792.0% | -4,255.6% | -1,801.8% | -1,123.1% | -1,349.6% | -1,253.3% | -2,479.5% | -2,666.8% | -1,665.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.